IQVIA Clocks 2.8% Sales Growth In Q4, Beats Street View By A Whisker

  • IQVIA Holdings Inc IQV posted Q4 sales of $3.74 billion, up 2.8% Y/Y on a reported basis and 7% at constant currency (CC), slightly above the consensus of $3.71 billion.
  • Technology & Analytics Solutions revenue increased 0.2% (4.7% CC) to $1.49 billion. 
  • Research & Development Solutions (R&DS) sales reached $2.06 billion, +5.9% (9.3% CC). 
  • Contract Sales & Medical Solutions revenue was down 7.1% (+2.0% CC) to $182 million.
  • R&DS contracted backlog as of December-end grew 9.6% Y/Y to $27.2 billion. The company expects approximately $7.3 billion of this backlog to convert to revenue in the next twelve months. 
  • IQVIA reported Q4 adjusted EPS of $2.78,+9%, beating the consensus of $2.76.
  • Guidance: IQVIA forecasts FY23 revenue to be $15.15-$15.40 billion, up 5.1%-6.9% on a reported basis and 5.0%-6.8% at constant currency, versus the consensus of $15.40 billion.
  • This revenue guidance assumes about 100 basis points of contribution from acquisitions and approximately $600 million of COVID-related revenue step-down versus 2022. 
  • The company expects Adjusted EBITDA of $3.625-$3.695 billion, up 8.3%-10.4%.
  • It sees adjusted EPS of $10.26-$10.56, compared to the consensus of $10.71.
  • Price Action: IQV shares are down 1.00% at $228.00 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEarnings BeatsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!